What’s News in Markets: Walmart Slumps, Omnicom Rallies, Moderna Comeback

21 Feb 2026 · 5 min · 4 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

```markdown

Podcast Episode Notes

WSJ Your Money Briefing

Episode Title

What’s News in Markets: Walmart Slumps, Omnicom Rallies, Moderna Comeback

Episode Overview In this episode, host Jack Pitcher discusses the key movements in the stock market, particularly focusing on Walmart's unexpected decline, Omnicom's positive performance due to cost-cutting measures, and Moderna's resurgence following an FDA decision. The episode highlights the week’s notable stock performances and the factors that influenced these movements.

---

Key Takeaways

Market Overview

  • The stock market experienced muted activity due to a shorter holiday week.
  • Tech and growth stocks showed signs of recovery after a prolonged sell-off, indicating a shift in investor sentiment away from defensive consumer staples stocks.

Major Stock Performances

  1. Walmart
  2. Experienced a notable decline after reporting strong earnings.
  3. Lost its position as the largest company in the U.S. by annual revenue to Amazon.
  4. Despite strong quarterly results, investors were disappointed due to high valuation and conservative guidance amidst economic uncertainty.
  5. Stock Performance: Dropped 8% for the week.
  1. Omnicom
  2. As the largest U.S. marketing services and advertising conglomerate, it announced significant cost-cutting measures, including a $900 million reduction, primarily through headcount cuts.
  3. Investors reacted positively, boosting its stock significantly.
  4. Stock Performance: Rose 15% on Thursday and 21% for the week, making it the best performer in the S&P 500.
  1. Moderna
  2. The company has been struggling since the peak of its COVID-19 vaccine sales.
  3. Initially faced a setback when the FDA declined to review its application for a new seasonal flu shot.
  4. Following a reversal where the FDA agreed to review the application after requiring additional testing for the elderly, sentiment shifted positively.
  5. Stock Performance: Increased by 6% on Wednesday and 18% for the week.

---

Market Indicators

  • S&P 500 Index: Rose by 1.1% for the week.
  • Dow Jones Industrial Average: Increased by 0.3%.
  • Nasdaq Composite: Gained 1.5%.

Sector Performance

  • Tech Sector: Best performing sector, indicating regained confidence.
  • Consumer Staples: Experienced a drop, signaling a rotation away from traditional safe-haven investments.

Regulatory Influence

  • The Supreme Court's decision to strike down President Trump's global tariffs was noted as a significant market development, although the ruling was largely anticipated.

---

Conclusion This episode provides a detailed analysis of the latest movements in the stock market, driven by corporate earnings and regulatory changes. The contrasting fortunes of Walmart, Omnicom, and Moderna exemplify the complexities of market reactions to earnings reports and broader economic signals.

For further updates, listeners are encouraged to follow WSJ's live market coverage. ```

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Market Overview

0:46 to 1:37

An overview of market movements and sector performances for the week.

“Our look at the biggest stock moves of the week and the news that drove them.”

Walmart's Earnings Impact

1:37 to 2:38

Discussion on Walmart's earnings report and its impact on shareholders.

“Last April, when they were first announced, the tariffs roiled markets.”

Omnicom's Cost-Cutting Strategy

2:38 to 3:43

Analysis of Omnicom's earnings and cost-cutting measures after acquisition.

“And that's made the stock expensive by traditional valuation metrics, which leaves it susceptible to disappointment if forecasts are anything less than stellar.”

Moderna's Stock Recovery

3:43 to 4:26

Exploration of Moderna's stock rebound following FDA's review decision.

“The vaccine maker Moderna has been reeling in the years since sales of its COVID-19 vaccine peaked, and the vaccine skepticism of Health and Human Services Secretary Robert F.”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00When you want your spring break to feel like... And your kid's pool day to feel like... And your hotel bed to feel like... Ooh, and room service to feel like... Because at Hilton, hospitality feels like...

0:19Jack Pitcher:Your cabana's ready. Would you like fresh towels? It matters where you stay. Book now at Hilton.com. Hilton. For this day. Hey listeners, your money briefing is on a break, but it will be back with more personal finance information for you in the future. Until then, here's the news moving markets this week. Hey listeners, it's Saturday, February 21st. I'm Jack Pitcher for The Wall Street Journal, and this is What's News in Markets. Our look at the biggest stock moves of the week and the news that drove them. Let's get to it. Stocks were relatively muted for the shorter holiday week. But there was no shortage of action under the surface, thanks to a big slate of corporate earnings.

1:05Investors seem to be regaining some confidence in tech and growth stocks, both of which have sold off for much of the year, over fears that rapid advancements in AI are going to render some software companies obsolete. But this week, communication services and information technology were the S &P 500's best performing sectors. Meanwhile, consumer staples companies, which are often seen as a safe haven, drop sharply. That signals a rotation away from the fear trade and back into other parts of the market. Then, of course, yesterday, the Supreme Court struck down President Trump's sweeping global tariffs.

1:42Last April, when they were first announced, the tariffs roiled markets. But a series of deals and carve-outs in the months since helped calm investors' fears. Stocks turned higher after the Supreme Court's decision, but analysts noted the ruling had been largely expected. And Trump said he'd keep the tariffs in place under a different authority. For the week, the S &P 500 rose 1.1%, while the Dow was 0.3 % higher. The tech-heavy Nasdaq added 1.5%.

2:16Walmart lost a notable crown when it reported earnings on Thursday. After 17 years of being the largest company in the U.S. by annual revenue, the retailer has officially been passed by Amazon. Still, Walmart's quarterly results were actually pretty strong, beating analysts' estimates for sales. Investors were not impressed. In the last three years, Walmart's shares have risen around 500 % thanks to remarkable results. And that's made the stock expensive by traditional valuation metrics, which leaves it susceptible to disappointment if forecasts are anything less than stellar. Walmart CFO John David Rainey told investors on Thursday that the company is giving conservative guidance because the economic backdrop is somewhat unstable.

3:02Walmart shares were among the S &P's worst performers this week, dropping 8%.

3:12Investors found more to like with Omnicom's earnings, but employees there may be feeling jittery. Omnicom is the biggest marketing services and advertising conglomerate in the U.S., and it told investors it was doubling its cost-cut target following its acquisition of competitor IPG. It expects to cut$900 million in costs this year, primarily by reducing head count. Investors cheered the news, sending Omnicom shares up 15 % on Thursday and 21 % for the week, making them the S &P's best performer.

3:48The vaccine maker Moderna has been reeling in the years since sales of its COVID-19 vaccine peaked, and the vaccine skepticism of Health and Human Services Secretary Robert F. Kennedy Jr. has been hitting its shares more recently. But a major reversal from the Food and Drug Administration on Wednesday helped turn sentiment around. Last week, the FDA said it would not review Moderna's application for a new seasonal flu shot. The decision shocked investors. But the regulator has since had a change of heart, saying it'll begin review of the new shot after Moderna agreed to additional testing in the elderly.

4:23Moderna shares rallied 6 % on Wednesday and 18 % on the week, putting them among the best performers in the S &P. And now you know what's news in markets this week. You can read about more stocks that moved on the week's news in our live markets coverage on WSJ.com. Today's show is produced by Alexis Moore with Deputy Editor Chris Sensley. I'm Jack Pitcher. Have a great weekend.

5:00of markets and investing. From the Fed's moves to market bubbles, we dive into the biggest deals, key players, and business news ahead. If you're looking for more news and tools that you can use to help navigate the markets, consider becoming a subscriber to The Wall Street Journal. Visit subscribe.wsj.com slash takeontheweek to subscribe now.

From the publisher

Why did Walmart fall on strong earnings? And how are Omnicom’s big cost cuts boosting its stock? Plus, will a major FDA reversal change Moderna’s fortunes? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them.Sign up for the WSJ's free Markets A.M. newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices

More from WSJ Your Money Briefing

All 57 episodes
What’s News in Markets: Walmart Slumps, Omnicom Rallies, Moderna ComebackWSJ Your Money Briefing · 5 min
Listen in VO